Clinical Response to Human Surfactant

1988 ◽  
pp. 143-149
Author(s):  
T. A. Merritt ◽  
M. Hallman ◽  
Y. E. Vaucher ◽  
C. Berry ◽  
A.-L. Jarvenpaa
Keyword(s):  
Clinical Response

Clinical Response to Questions Regarding Outcomes and Therapy Efficacy

2010 ◽  
Vol 20 (3) ◽  
pp. 76-83 ◽  
Author(s):  
Joseph Donaher ◽  
Tom Gurrister ◽  
Irving Wollman ◽  
Tim Mackesey ◽  
Michelle L. Burnett
Keyword(s):  
Risk Factors ◽  
Clinical Response ◽  
Speech Language Pathologists ◽  
Specific Therapy ◽  
Therapy Efficacy ◽  
Therapy Program ◽  
Adults Who Stutter ◽  
Cure Rates

Parents of children who stutter and adults who stutter frequently ask speech-language pathologists to predict whether or not therapy will work. Even though research has explored risk-factors related to persistent stuttering, there remains no way to determine how an individual will react to a specific therapy program. This paper presents various clinicians’answers to the question, “What do you tell parents or adults who stutter when they ask about cure rates, outcomes, and therapy efficacy?”

Primary chemoprevention of familial adenomalous polyposis: Stratification of clinical response to sulindac by mucosal prostanoid levels

2001 ◽  
Vol 120 (5) ◽  
pp. A253-A253
Author(s):  
V YANG ◽  
R CASERO ◽  
D GEIMAN ◽  
W HUBBARD ◽  
L HYLIND ◽  
...  
Keyword(s):  
Clinical Response

Do Second-Time Users of Topical Imiquimod have a More Rapid Onset of Clinical Response?

2018 ◽  
Vol 2 (3) ◽  
pp. 156-161
Author(s):  
Stacy L McMurray ◽  
Matthew Reynolds ◽  
Matthew S Dinehart ◽  
Scott M Dinehart
Keyword(s):  
Clinical Response ◽  
Time Use ◽  
Γδ T Cells ◽  
Rapid Onset ◽  
Primary Objective ◽  
Imiquimod Cream ◽  
Actinic Keratoses ◽  
Topical Imiquimod ◽  
Primary Endpoints ◽  
Time To Onset

Introduction: Topical imiquimod is commonly used in dermatology for treatment of actinic keratoses (AK). Prior studies in humans and mice have suggested the potential for immune recall with imiquimod based on higher degrees of AK clearance and activation of memory γδ T-cells in a mouse model. Anecdotal reports suggest a more rapid time-to-onset of clinical response with second time use of imiquimod. However, the potential for immune recall demonstrated by time-to-onset of clinical response has not been formally investigated.Objective:  The primary objective of this study was to determine if there is a difference in time-to-onset of clinical response between naïve and prior users of topical imiquimod for the treatment of actinic keratoses.Methods:  A total of 92 patients were treated with 5% imiquimod cream for actinic keratoses of the head and neck. Patients were instructed to apply 5% imiquimod cream to the affected areas once daily until reaching a therapeutic endpoint of crusting/scabbing. The primary endpoints in the study were time (days) to onset of erythema and time to onset of crusting/scabbing. Results were self-reported.Results:  The average time (days) to onset of erythema was 5.48 ± 3.19 days in naïve users and 4.7 ± 2.91 days in prior users (p= 0.22). Average time to onset of crusting/scabbing was 9.2 ± 4.34 days in naïve users and 9.02 ± 3.65 days in prior users (p=0.35).Conclusion:  Our study revealed there is no difference in time-to-onset of erythema or scabbing/crusting with second-time use of imiquimod.  While immune recall may be possible with use of imiquimod, the results of this study indicate that it may be independent of time-to-onset of clinical response.  

Sign in / Sign up

Export Citation Format

Share Document